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Abstract
Introduction: Estrogen receptor-a (ER) and human epidermal growth factor receptor 2 (HER2) positivity are
inversely correlated by standard criteria. However, we investigated the quantitative relation between ER and HER2
expression at both RNA and protein levels in HER2+ve and HER2-ve breast carcinomas.
Methods: ER and HER2 levels were assessed with immunohistochemistry (IHC) and (for HER2) fluorescent in situ
hybridization (FISH) and by quantitative reverse transcription-polymerase chain reaction (q-RT-PCR) in formalin-fixed
primary breast cancers from 448 patients in the National Cancer Research Institute (NCRI) Adjuvant Breast Cancer
Trial (ABC) tamoxifen-only arm. Relations at the RNA level were assessed in 1,139 TransATAC tumors.
Results: ER and HER2 RNA levels were negatively correlated as expected in HER2+ve (IHC 3+ and/or FISH-
amplified) tumors (r = -0.45; P = 0.0028). However, in HER2-ve tumors (ER+ve and ER-ve combined), a significant
positive correlation was found (r = 0.43; P < 0.0001), HER2 RNA levels being 1.74-fold higher in ER+ve versus ER-ve
tumors. This correlation was maintained in the ER+veHER2-ve subgroup (r = 0.24; P = 0.0023) and confirmed in this
subgroup in 1,139 TransATAC tumours (r = 0.25; P < 0.0001). The positive relation extended to IHC-detected ER in
ABC: mean ± 95% confidence interval (CI) H-scores were 90 ± 19 and 134 ± 19 for 0 and 1+ HER2 IHC categories,
respectively (P = 0.0013). A trend toward lower relapse-free survival (RFS) was observed in patients with the lowest
levels of ER and HER2 RNA levels within the ER+veHER2-ve subgroup both for ABC and TransATAC cohorts.
Conclusions: ER and HER2 expression is positively correlated in HER2-ve tumors. The distinction between HER2+ve
and HER2-ve is greater in ER-ve than in ER+ve tumors. These findings are important to consider in clinical trials of
anti-HER2 and anti-endocrine therapy in HER2-ve disease.
Trial Registration: Clinical trial identifier: ISRCTN31514446.
Introduction
Estrogen receptor-a (ER) and the human epidermal
growth factor receptor 2 (HER2) are the two key bio-
markers that segregate the most distinct biologic sub-
groups of breast cancer and presently direct adjuvant
treatment of primary disease. ER is expressed in
approximately 80% of all breast cancers [1]. Amplifica-
tion or overexpression of HER2 or both are present in
about 15% of breast cancers [2,3]. The importance of
these receptors as predictive biomarkers has been
underpinned by the American Society of Clinical Oncol-
ogy/College of American Pathologists (ASCO/CAP),
who have issued guidelines for their accurate testing
[4,5].
In HER2-overexpressing (HER2+ve) metastatic cancer,
treatment with trastuzumab in combination with che-
motherapy improves time to progression and survival
[6]. In the adjuvant setting, sequential or concurrent
trastuzumab improves disease-free survival and, in some
trials, overall survival [7-9]. Despite its recognized bene-
fit in HER2+ve disease, some evidence suggests this ben-
efit also extends to HER2-non-overexpressing/normal
(HER2-ve) cancer. Paik and colleagues [10] showed that
patients with normal HER2 copy number and protein
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levels lower than 3+ by immunohistochemistry (IHC)
may also benefit from trastuzumab. The NSABP B-47
(NCT 01275677) trial is now recruiting women with
node-positive or high-risk node-negative HER2-low
(IHC 1+ or IHC 2+ FISH-ve) invasive breast cancer to
address these observations prospectively.
HER2 overexpression is associated with partial resis-
tance to endocrine treatment [11-15]. The complex
cross-talk between ER and HER2 pathways might be an
underlying cause of resistance, although the intrinsic
biologic mechanism is poorly understood [16,17]. Some
aspects of the relation between ER and HER2 expression
have been described previously. ER and HER2 positivity
are inversely correlated [18-20], leading to approxi-
mately 10% of ER+ve tumors being HER2+ve [21] and
about 50% of HER2+ve being ER+ve [22]. ER expression
has also been shown to be quantitatively higher in
HER2-ve than in HER2+ve tumors among ER+ve
tumors; however, few analyses have been conducted on
the quantitative relation within the HER2-ve subgroup
[23]. In addition, little evidence exists for the biologic
importance of IHC 1+ versus 0 levels of HER2 expres-
sion, with both categories currently classified as HER2-
ve. It is unclear whether IHC 1+ cases arise as an arti-
fact of staining or reflect a true difference in expression
[10]. Furthermore, few data examine the relation
between transcript levels and protein expression by IHC
for HER2, even though this relation is well documented
for ER [24].
We have therefore (a) characterized gene expression,
protein, and/or amplification levels for ER and HER2
individually; (b) explored the relation between ER and
HER2 at both the protein and RNA levels, irrespective
of the samples ER and HER2 status; and (c) evaluated
the significance of transcript levels within the HER2-ve
population and, in particular, the ER+veHER2-ve/sub-
group in terms of relapse-free survival in a set of 448
early breast cancers from the NCRI Adjuvant Breast
Cancer (ABC) Trial-Tamoxifen Late Relapse Study
[25,26].
Materials and methods
Sample collection
The ABC Trial was a randomized, controlled phase III
clinical trial comparing the addition of (a) chemotherapy
(with or without elective ovarian ablation or suppres-
sion), and (b) ovarian ablation or suppression (with or
without elective chemotherapy) to prolonged treatment
with tamoxifen in women with early-stage breast cancer
[25,26]. All patients were accrued between 1992 and
2000 and received at least 5 years of tamoxifen (20 mg/
day), irrespective of ER status. The ABC Tamoxifen Late
Relapse (TLR) study was designed as a retrospective
translational research study within the main ABC trial
to identify predictive biomarkers of late relapse. Four
hundred and forty-eight archival formalin-fixed paraffin-
embedded (FFPE) tumor blocks were obtained from par-
ticipating centers for patients from the tamoxifen-alone
arm. This study was approved by the Multicentre
Research Ethics Committee, and all patients included
gave informed consent. Results on the primary aims of
the ABC TLR study will be published separately.
Immunohistochemistry and fluorescence in situ
hybridization
Tissue microarrays (TMAs) were constructed by using
single cores (1-mm diameter) taken from donor blocks
containing sufficient invasive tumor. Serial 4-μm sec-
tions from the TMAs were used for immunohistochem-
ical and fluorescence in situ hybridization (FISH)
analyses.
ER was measured with immunohistochemistry (IHC)
by using clone 6F11 (dilution 1/40; Leica Microsystems,
Newcastle Upon Tyne, UK) and quantified with H-score
[27]. ER positivity was defined as H-score ≥ 1, which
corresponds closely to an Allred score ≥ 3 and to the
recently recommended IHC positivity cut-off, according
to ASCO/CAP guidelines of > 1% positive cells [4].
HER2 protein levels were assessed with the HercepT-
est (Dako Cytomation, Carpinteria, CA, USA) and con-
sidered positive if IHC staining was 3+, equivocal for
IHC 2+, and negative for IHC 0 and 1+, as per ASCO/
CAP guidelines [5]. HER2 amplification was measured
with FISH by using the Pathvysion HER-2 DNA Probe
kit (Abbott Molecular, Inc., Des Plaines, IL, USA) and
considered positive, equivocal, or negative if FISH ratios
(HER2/CEP17) were > 2.2, 1.8 to 2.2, or < 1.8, respec-
tively [5]. For all markers, only the invasive tumor com-
ponent was assessed.
Quantitative reverse transcription-PCR
RNA extraction was performed on two 10-μm sections
taken from each of the tumor blocks by using the
RNeasy FFPE RNA Isolation kit (Qiagen, Crawley, UK),
according to the manufacturer’s recommendations,
except for an initial incubation in xylene (30 minutes,
37°C) for complete removal of paraffin. RNA was addi-
tionally treated to remove genomic DNA contamination
(1 hour, 37°C) with 6 U of rDNase I (DNA-free Kit;
Applied Biosystems, Foster City, CA, USA). RNA quality
and quantity were evaluated by using the Agilent 2100
Bioanalyser (Expert Software version B.02.03; Agilent
Technologies, Edinburgh, UK).
Four hundred nanograms of RNA (in triplicate) was
reverse transcribed with SuperScript III by using ran-
dom primers (Invitrogen, Paisley, UK). Twenty nano-
grams of cDNA was analyzed with quantitative reverse
transcription-PCR (qRT-PCR) in triplicate by using the
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ABI Prism 7900HT (Applied Biosystems). Reference
genes consisted of MRPL19, TFRC, and TBP, as pre-
viously described [28]. The gene-expression assays and
primers/probes used are detailed in Additional file 1,
Table S1. ER and HER2 transcript data were normalized
to the geometric mean of three reference genes
(MRPL19, TFRC, and TBP) [29].
Statistical analysis
ER and HER2 RNA data were log10 transformed. Spear-
man rank correlation was used to determine the correla-
tion between protein and RNA levels for both ER and
HER2 and between FISH ratio and RNA levels for
HER2 only. Differences between subpopulation means
were assessed with the Mann-Whitney test, and analysis
of variance for multigroup comparisons used the Krus-
kal-Wallis test with GraphPad Prism 5.0a software (La
Jolla, CA, USA).
Analysis of time-to-event data was undertaken by
using Cox regression, multivariable fractional
polynomials being used to investigate nonlinear relations
and interactions between outcome and continuous para-
meters for ER and HER2 RNA levels [30] and with
STATA 10.1 software (College Station, TX, USA). Tran-
script levels for ER and HER2 by using the Oncotype
DX test were available for 1,139 HER2-ve tumors from
the TransATAC study [31,32] for validation of results
presented here. A post hoc hazard ratio test was used to
detect differences in outcome between subgroups. All
tests were two-sided and considered significant for P
values < 0.05.
Results
Samples available
A complete set of results for ER and HER2 using qRT-
PCR, IHC, and FISH (for HER2 only) was available for
257 samples, with the exception of 25 cases in which
HER2 was available by only either IHC or FISH. Rea-
sons for nonavailability for each marker are shown in
the CONSORT diagram (Figure 1). HER2 IHC 2+ cases
448 patients eligible from the tamoxifen alone 
arm of the ABC trial
18 samples insufficient invasive tumour
425 samples for qRT-PCR 430 samples for IHC and FISH
5 samples given 
preference for 
TMA construction 
113 samples 
insufficient RNA yield 
7 samples ER 
not possible 
305 samples ER RNA 
levels available
312 samples HER2 
RNA levels available
360 samples ER IHC 
data available
368 samples HER2 IHC 
data available
330 samples HER2 
FISH data available
70 samples ER 
not possible
62 samples HER2 
IHC not possible
100 samples HER2 
FISH not possible
257 samples available with matched 
results on all techniques used 
Figure 1 CONSORT flow chart of the ABC Tamoxifen Late Relapse Study in which the number of samples with data available for ER
and HER2 by qRT-PCR, IHC, and FISH (for HER2 only) are shown. ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2,
human epidermal growth factor receptor 2; IHC, immunohistochemistry; qRT-PCR, quantitative reverse-transcription polymerase chain reaction.
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in which no FISH data were available were excluded
from analysis where relevant (n = 4). All data presented
are in relation to these matched results. The demo-
graphic characteristics of this population are shown in
Table 1. Median follow-up was 8.1 years (interquartile
range (IQR) = 5.2 to 10.3 years).
ER- and HER2-positive/negative status by IHC and FISH
Sixty-seven percent of cases were ER+ve (n = 173), and
the remaining 33% were negative (n = 84). HER2 by IHC
was positive for 15% (IHC 3+; n = 37), equivocal for 8%
(IHC 2+; n = 19), and negative for 77% of cases (IHC 0,
38%; n = 96; 1+, 39%, n = 101). HER2 was amplified in
15% (n = 34) and remained equivocal in 1% of cases (n =
3), which could not be assessed in 20 further cells
because of scarce invasive tumor. Overall, HER2 was
positive by either IHC or FISH in 16% of cases (n = 42).
HER2 distribution by IHC and FISH according to posi-
tive/negative status is shown in Table 2.
Correlation between RNA and IHC (FISH) levels for ER and
HER2
The measurement of ER and HER2 transcript levels by
qRT-PCR in FFPE tissue was previously validated in our
laboratory [28].
ER was highly correlated at the RNA and protein
levels (Figure 2a; Spearman R = 0.76; P < 0.0001). This
correlation was less strong but still highly significant in
the ER+ve population only (blue symbol, Figure 2a;
Spearman R = 0.53; P < 0.0001). ER RNA levels were a
mean 9.52-fold higher in IHC-positive than in IHC-
negative tumors, although levels between the two cate-
gories overlapped (Figure 2b; P < 0.0001).
HER2 transcript and amplification levels were signifi-
cantly correlated (Figure 2c; Spearman R = 0.41; P <
0.0001), and this correlation was also found to extend to
the FISH-positive (FISH+ve) population only, albeit not
so strongly (blue symbol, Figure 2c; Spearman R = 0.34;
P = 0.047). HER2 transcript levels were a mean 6.52-
fold higher in FISH+ve than in FISH-negative (FISH-ve)
tumors (P < 0.0001). Figure 2d shows HER2 RNA levels
according to each of the IHC categories (0, 1+, 2+, and
3+). Despite substantial overlap between the groups, a
multigroup comparison showed a significant difference
between the four categories (P < 0.0001). HER2 RNA
levels were significantly different between each of the
adjacent IHC categories: 0 versus 1+, P = 0.0070; 1+
versus 2+, P = 0.0025; 2+ versus 3+, P < 0.0001.
Relation of ER with HER2 gene expression
The relation of ER with HER2 at the gene-expression
level was investigated separately in HER2+ve (FISH+ve
and/or IHC 3+; n = 42) and HER2-ve cases (FISH-ve
and IHC 0/1+/2+; n = 211). Four IHC 2+ cases were
further excluded, for which FISH data were unavailable
for confirmation. The analyses included both ER+ve and
ER-ve cases.
The expected significant inverse correlation between
ER and HER2 RNA levels in the HER2+ve group was
observed (Spearman R = -0.45; P = 0.0028; Pearson R =
-0.32; P = 0.041; Figure 3). In contrast, a significant and
equally strong positive correlation was found between
ER and HER2 RNA levels in the HER2-ve group (Spear-
man R = 0.43; P < 0.0001; Pearson R = 0.51; P < 0.0001;
Figure 3).
The direct relation between ER and HER2 transcript
levels in HER2-ve tumors was also found in the relation
between ER RNA levels and HER2 at the protein level
(Figure 4a). ER RNA levels in the six HER2 categories
were significantly different by multigroup comparison (P
< 0.0001), with ER RNA levels being higher in the
Table 1 Demographic characteristics of patients included
in the ABC Tamoxifen Late Relapse Study
Variable N = 257
Age in years, mean ± SD 54.8 ± 8.0
Tumor size, n (%)
< 2 cm 122 (48.4)
2-5 cm 123 (48.8)
> 5 cm 7 (2.8)
Grade, n (%)
Well differentiated 22 (8.6)
Moderately differentiated 110 (42.8)
Poorly differentiated 107 (41.3)
Unknown differentiated 18 (7.0)
Nodal status, n (%)
Negative 100 (40.8)
1 to 3 nodes positive 106 (43.3)
4+ positive 39 (15.9)
Local ER status, n (%)
Positive 133 (51.7)
Negative 84 (32.7)
Unknown 40 (15.6)
A complete set of results for ER and HER2 by using qRT-PCR, IHC, and FISH
(for HER2 only) was available. ER, estrogen receptor; SD, standard deviation.
Table 2 HER2 distribution by IHC and FISH
HER2 FISH
Positive Negative Equivocal Not
available
Total
IHC Positive (3+) 29 5 2 1 37
Equivocal (2+) 2 13 - 4 19
Negative (1+) 2 91 1 7 101
Negative (0) 1 86 - 9 96
Not available - 4 - - 4
Total 34 199 3 21 257
FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor
receptor 2; IHC, immunohistochemistry.
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A B
C D
P=0.0025
P=0.007
P<0.0001
Figure 2 Relation of RNA levels. (a) Relation of ER RNA levels (qRT-PCR) with protein expression assessed with IHC (H score). (b) ER RNA levels
according to IHC status. ER-ve (IHC H score ≤ 1); n = 84; and ER+ve (IHC H score > 1); n = 173. (c) Relation of HER2 RNA levels (qRT-PCR) with
HER2 amplification levels (FISH). HER2+ve, n = 34; HER2-ve, n = 199; and HER2 equivocal, n = 3. (d) HER2 RNA levels according to IHC
HercepTest categories. IHC 0, n = 96; IHC 1+, n = 101; IHC 2+, n = 19; and IHC 3+, n = 37. Means with 95%CI are shown. CI, confidence interval;
ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; qRT-
PCR, quantitative reverse-transcription polymerase chain reaction.
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HER2 IHC 1+ and 2+FISH-ve group than in the IHC 0
group (P = 0.01 and P = 0.15, respectively). ER RNA
levels in each of the HER2 IHC categories 0, 1+, and 2+
were nonetheless significantly higher than in IHC 3+
FISH+ve tumors (P = 0.0095, P < 0.0001, and P = 0.011,
respectively).
In ER+ve disease, ER RNA levels were a mean 2.73-
fold higher in HER2-ve than in HER2+ve tumors (8.21
versus 3.01; P = 0.0014; Table 3; Additional file 2: Figure
S1a). In HER2-ve tumors, the RNA level of HER2 was
higher in ER+ve than in ER-ve tumors, with a mean fold
difference of 1.75 (1.09 versus 0.62; P < 0.0001; Addi-
tional file 2: Figure S1b). In ER+ve disease, HER2 RNA
Figure 3 Correlation of ER and HER2 transcript levels (qRT-PCR). HER2-ve is defined as HER2 FISH-ve and IHC 0/1+/2+; n = 211. HER2+ve is
defined as HER2 FISH+ve and/or IHC 3+; n = 42. ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth
factor receptor 2; IHC, immunohistochemistry; qRT-PCR, quantitative reverse-transcription polymerase chain reaction.
Table 3 Number (%) of samples within the positive and
negative subgroups for ER and HER2 biomarkers
Subgroups Number
(%)
ER RNA levelsa HER2 RNA
levelsa
ER+HER2-ve 155 (60) 8.21 (6.59-9.83) 1.09 (0.96-1.21)
ER+HER2
+ve
18 (7) 3.01 (1.89-4.13) 6.63 (3.01-10.2)
ER-HER2-ve 60 (23) 0.93 (0.48-1.37) 0.62 (0.47-0.77)
ER-HER2+ve 24 (9) 0.50 (9.04 × 10-2 -
0.92)
8.51 (6.60-10.4)
aMean (95% CI) values are shown. ER+ve, IHC H-score ≥ 1; HER2-ve, FISH-ve
and IHC 0/1+/2+; HER2+ve, FISH+ve and/or IHC 3+. CI, confidence interval; ER,
estrogen receptor; FISH, fluorescence in situ hybridization; HER2, human
epidermal growth factor receptor 2; IHC, immunohistochemistry.
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levels were 6.08-fold higher in HER2+ve than in HER2-
ve tumors (6.63 versus 1.09; P < 0.0001). This difference
was more evident in the ER-ve population, in which a
13.7-fold difference was found between HER2+ve and
HER2-ve tumors (8.51 versus 0.62; P < 0.0001).
The positive correlation observed between ER and
HER2 transcript levels in HER2-ve samples was also
maintained, albeit more weakly when that group was
further divided to include ER+ve tumors only (Spear-
man R = 0.24; P = 0.0023). This finding was present to
a similar degree in this ER+ve/HER2-ve subgroup in
TransATAC (Spearman R = 0.25; P < 0.00001). ER H-
scores were significantly higher in HER2 IHC 1+ than in
IHC 0 tumors (mean ± SEM, 134 ± 10 and 90 ± 9,
respectively; P = 0.0013; Figure 4b), suggesting further
evidence for a direct relation between the two biomar-
kers in HER2-ve disease.
Prognostic relevance of ER and HER2 RNA levels
We explored the potential clinical importance of ER and
HER2 expression in the HER2-ve cases (n = 197). The
log-rank test showed a significant difference in time to
relapse (TTR) between groups, defined by quartiles of
ER RNA levels (P = 0.03), with shortest TTR in those
with the lowest ER quartile, which included most of the
ER-ve cases (Figure 5a). TTR was also significantly dif-
ferent according to HER2 levels (P = 0.04), being higher
in the 50% of patients with the lowest HER2 RNA levels
(Figure 5b).
Considering only the ER+ve HER2-ve cases, a test for
trend showed a nonsignificant trend to a difference in
TTR between the quartiles of RNA levels for ER and
HER2 (Figure 5c, ptrend = 0.058; and Figure 5d, ptrend =
0.069, respectively). Comparing the lowest quartile of
HER2 RNA levels with the others in that subgroup, a
A B
Figure 4 RNA and protein levels. (a) ER RNA levels and (b) ER protein levels according to HER2 protein and gene-amplification levels (IHC
HercepTest and FISH, respectively); IHC 0, n = 96; IHC 1+, n = 101; IHC 2+ FISH-ve, n = 13; IHC 2+ FISH+ve, n = 2; IHC 3+ FISH-ve, n = 5; IHC 3+
FISH+ve, n = 29; IHC 3+, n = 37. Means with 95% CI are shown (95% confidence intervals for IHC2+ FISH+ve subgroup are 4a, -5.1 to 5.8, and
4b, -892.2 to 1045; these were omitted for ease of visualization). CI, confidence interval; ER, estrogen receptor; FISH, fluorescence in situ
hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; qRT-PCR, quantitative reverse-transcription
polymerase chain reaction.
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ABC
Quartiles according to ER RNA Levels Quartiles according to HER2 RNA Levels
ER+ve HER2-veE
Lowest Highest
ptrend=0.02
ER+ve HER2-veD
ptrend=0.069
Lowest Highest
B All ER HER2-ve
p=0.04
Lowest Highest
All ER HER2-veA
Lowest Highest
p=0.03
ER+ve HER2-veC
Lowest Highest
ptrend=0.058
Trans
ATAC
ABC
ER+ve HER2-veF
Lowest Highest
ptrend=0.2
ABC
Figure 5 Kaplan-Meier plots for relapse-free survival in HER2-ve cases. (a, b) Relapse-free survival by ER and HER2 RNA quartiles (qRT-PCR),
respectively, in the HER2-ve population of the ABC study, irrespective of ER status. (c, d) Relapse-free survival by ER and HER2 RNA quartiles,
respectively, in the subgroup of ER+ve HER2-ve cases of the ABC study. (e, f) Relapse-free survival by ER and HER2 RNA quartiles, respectively, in
the ER+ve HER2-ve cohort of the TransATAC study. First quartile defined as the lowest RNA levels for ER and HER2. N.B.: The y-axis scale in the
ABC study is different from that in the TransATAC study. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; qRT-PCR,
quantitative reverse-transcription polymerase chain reaction.
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significant difference in TTR at 5 years was found; this
became nonsignificant at 10 years (HR (95% CI), 2.45
(1.17 to 5.12) and 1.53 (0.82 to 2.86), respectively).
In the TransATAC study, a similar pattern was
observed in the ER+ve HER2-ve cohort. A significant
difference in TTR between quartiles of ER RNA levels
was found (Figure 5e, ptrend = 0.02), with the lowest
quartile showing the shortest TTR, which was not con-
sistently observed throughout the 10-year follow-up in
ABC, possibly because of the small number of cases.
With regard to HER2 RNA levels, a nonsignificant trend
to a difference in TTR between quartiles was observed
(Figure 5f; ptrend = 0.2). The lowest quartile of HER2
levels showed a trend to shortest TTR at 5 and 10 years
(HR (95% CI), 0.83 (0.51 to 1.36) and 0.76 (0.55 to
1.06), respectively). A significant relation between ER
protein levels and outcome in TransATAC has been
published [21].
Discussion
To our knowledge, the present study is the first to
report a direct relation between ER and HER2 at the
RNA level in HER2-ve tumors. The TransATAC set of
material provided confirmation of this observation, and
two other studies support this relation at the protein
level but do not examine it in detail [23,33].
ER and HER2 status is used to guide the decision-mak-
ing process for patient treatment, but clinical trials have
been conducted (for example, letrozole ± lapatinib,
EGF30008 [34]) and are under way (chemotherapy ±
trastuzumab, NSABP-B47) of HER2-targeted agents in
HER2-ve disease in which the relations between (a) ER
and HER2 and (b) HER2 IHC and mRNA expression are
not well described. The present study revealed novel data
that, as well as being of general biologic interest, may be
important to the interpretation or conduct of these trials,
respectively. In addition, the higher HER2 RNA expres-
sion in the ER+ve HER2-ve tumors might provide an
escape route for such tumors during endocrine therapy.
Here, ER and HER2 gene expression were measured
on FFPE material with qRT-PCR. This technique allows
a quantitative evaluation of biomarker expression and
generation of data as a continuous variable, as opposed
to IHC, which, other than by use of specialist techniques
such as AQUA [35], at most provides a semiquantitative
reading, with categorization of data potentially leading
to loss of information. Previous data from our laboratory
had demonstrated an excellent correlation between
fresh-frozen and FFPE materials for both ER and HER2
[28]. The reliability of gene expression measured with
qRT-PCR in FFPE material, including ER and HER2
expression, has been extensively validated [24] and is
now included in commercial prognostic tools, such as
Oncotype DX [36].
The well-described inverse relation between ER and
HER2 based on status and the negative quantitative rela-
tion between ER and HER2 expression in HER2+ve
tumors was confirmed in our study [18-20]. Given this,
the positive correlation between the RNA levels of ER
and HER2 for HER2-ve patients was surprising but was
confirmed as being present at a protein (IHC) level. The
validity of the direct relation between ER and HER2
RNA levels was confirmed in the large TransATAC ser-
ies of ER+veHER2-ve tumors. Data in the literature sup-
port this relation. Konecny et al. [23] reported, but did
not characterize further, a significant positive correlation
between these markers at the protein level among
HER2-ve tumors within their cohort A. Harigopal et al.
[33] also described a positive correlation between ER
and HER2 detected with AQUA in tumors expressing
ER and HER2 at the lowest quartiles of expression. In
addition, the bottom (low) as well as the top (high) dec-
iles of HER2 expression were significantly associated
with worse disease-free survival. Our results also show
worse relapse-free survival for the HER2-ve tumors
expressing HER2 at the lowest levels. This relation with
outcome was relatively modest but was consistent with
the validation analyses undertaken with the TransATAC
cohort. The significantly worse outcome shown for the
lowest ER quartile probably reflects that this group is
largely ER-ve; this effect was lost when the analysis was
confined to ER+ve tumors.
Currently, HER2 diagnostics for selecting patients for
trastuzumab or other HER2-targeted treatments are
based on a dichotomous categorization whereby patients
with FISH+ve or IHC 3+/2+FISH+ve tumors are
deemed positive. The data presented here reveal widely
overlapping transcript levels between these convention-
ally HER2-positive and -negative categories, as well as
between the “negative” IHC subcategories of 0, 1+, and
2+FISH-ve. Brase et al. [37] and Paik et al. [10] also
showed a continuous expression of HER2 RNA levels
according to IHC/FISH categories. It is notable that
although a major overlap exists between the groups, the
HER2 IHC 1+ category shows significantly higher RNA
levels than the IHC 0 category (Figure 2d), suggesting
that some biologic meaning is associated with the
separation of these IHC staining groups, rather than
being merely a staining artefact. Although its impor-
tance is at present uncertain, Paik and colleagues [10]
found HER2-ve patients to benefit from trastuzumab to
a similar extent as do HER2+ve patients [10]. This find-
ing will be prospectively addressed in the recently
initiated NSABP-B47 study of trastuzumab in HER2
IHC 1+ or IHC 2+ FISH-ve cases (NCT 01275677). Our
results indicate that, at least at a transcript level, these
groups are only modestly different from HER2 IHC 0
cases. An assessment of the quantitative level of HER2
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at the transcript level is merited, in that and other stu-
dies of this population, as a possible predictor of benefit.
This continuous expression of HER2 at a transcript
level, as noted earlier, is also seen with techniques such
as AQUA and may have implications for the targeting
of agents such as the HER2-cytotoxic conjugate TDM-1,
which may rely more on the level of binding to cells
than an opposing underlying HER2-driven growth [38].
Our data also have implications for the confidence in
ascribing of HER2 positivity in diagnostics. The differ-
ence in HER2 RNA levels between HER2+ve and HER2-
ve tumors was more evident in the ER-ve than in the
ER+ve population (13.7-fold versus 6.1-fold difference,
respectively). These data suggest that the distinction of
HER2+ve from HER2-ve tumors in pathologic diagnosis
may be subject to greater error in ER+ve than in ER-ve
patients.
Our study has some limitations. Single-core TMAs
were used for ER and HER2 IHC assessment, and
although the expression of these markers is not highly
heterogeneous, some relations may be weakened. It is
unlikely, though, that this might lead to false-positive
relations. These IHC/FISH TMA results were compared
with qRT-PCR results from whole sections, and this is
also likely to add to the variability observed. However,
given that a false-positive finding has been excluded by
the TransATAC validation dataset, this variability is
most likely to reduce the strength of the reported
relations.
Conclusions
ER and HER2 are positively correlated at both protein
and RNA levels in HER2-ve tumors, contrary to their
recognized negative relation in HER2+ve disease. The
distinction between HER2+ve and HER2-ve is greater in
ER-ve than in ER+ve tumors. These findings may lead
to greater diagnostic uncertainties in ER+ve patients and
are important to consider in clinical trials of anti-HER2
and anti-endocrine therapy in HER2-ve disease.
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